Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients

This study aimed to investigate the role of bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) who had developed acquired resistance to EGFR-TKIs therapy that manifested as malignant pleural effusion (MPE). In total, 86 patients were included. 47 patients received bevacizumab p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tao, Li, Aiwu, Su, Chunxia, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617537/
https://www.ncbi.nlm.nih.gov/pubmed/28977977
http://dx.doi.org/10.18632/oncotarget.16061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617537/
https://www.ncbi.nlm.nih.gov/pubmed/28977977
http://dx.doi.org/10.18632/oncotarget.16061

Ejemplares similares